Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Helmerich & Payne Inc. Common Stock (HP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Helmerich & Payne Inc. Common StockTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Helmerich & Payne Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Helmerich & Payne Inc. Common Stock trades at $38.58 (market cap $3.86B), while State Street SPDR S&P Biotech ETF trades at $147.22 (market cap $10.05B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.6× Helmerich & Payne Inc. Common Stock's market cap, and Helmerich & Payne Inc. Common Stock pays a 2.59% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Helmerich & Payne Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.

HPXBI
Market Cap
$3.86B$10.05B
Volume
870,37110,367,649
Sector
EnergyBroad Market / Factor
52-Week High
$47.64$169.55
52-Week Low
$23.11$107.32
Typical Hold Time
0 Days39 Days
Enterprise Value
$5.49B—
Dividend Yield
2.59%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Helmerich & Payne Inc. Common Stock

No Aura AI signal available yet.

State Street SPDR S&P Biotech ETF

XBI trades at $146.8, down 3.04% today amid a bearish technical signal. The ETF's modified equal-weight structure provides exposure to over 150 biotech names, benefiting from M&A activity and positive clinical catalysts. Recent news highlights a 76% prior-year rally and optimism around cancer vaccine breakthroughs from Merck and Moderna. However, the ETF carries higher volatility and expense ratios compared to broader healthcare funds.

Outlook remains mixed with technical indicators bearish but fundamental catalysts present. Investment opportunity lies in targeted biotech exposure and sector innovation, though risks include high volatility, regulatory uncertainty, and reliance on clinical trial successes. Analyst consensus is neutral with 100% hold rating, suggesting cautious optimism amid recent price declines.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HP
100% Buy0% Sell
Avg holding period · 0 Days
XBI
100% Buy0% Sell
Avg holding period · 39 Days

About Helmerich & Payne Inc. Common Stock

Helmerich & Payne, Inc. is a US drilling contractor that designs, builds, and operates high-performance land and offshore drilling rigs for oil and gas producers worldwide.

Read more on HP →

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI →